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1. INTRODUCTION 
                  Analytical chemistry is basically concerned with the determination of the 
chemical composition of matter however, identification of substances, the elucidation 
of its structure and quantitative analysis of composition, are the aspects covered by 
modern analytical techniques. By means of analytical techniques both qualitative 
analysis (the presence or absence of one or more elements) and quantitative 
analysis (how much amount is present) can be done. 
1.1. CHROMATOGRAPHY 
               The word chromatography is derived from the Greek letters chromos 
meaning color and the graph means color writing. The initial use of the terms is 
attributed to T Swett. It can be defined as “a separation process that is achieved by 
distribution of substance between two phases that is stationary phase and mobile 
phase.” 
IMPORTANCE OF CHROMATOGRAPHY 
Chromatography is one of the most powerful and versatile analytical techniques 
available to the modern chemist. Its power arises from its capacity to determine 
quantitatively many individual components present in a mixture in a single one 
analytical run. Its versatility comes from its capacity to handle wide variety of 
samples that may be gaseous, liquid or solid in nature. The sample can range in 
complexity from a single substance to a multi component mixture containing widely 
different chemical species. Another aspect of versatility is that the analysis can be 
carried out on a very costly complex instrument and on the other hand on a simple 
inexpensive thin layer plate. 
1.2. HIGH PERFORMANCE LIQUID CHROMATOGRAPHY METHOD 
         HPLC is introduced commercially in 1969 and since then it has undergone 
extensive modifications and innovation which lead to the emergence as the foremost 
analytical tool for quantitative analysis. HPLC is a type of liquid chromatography that 
employs a liquid mobile phase and a very finely divided stationary phase. In order to 
obtain a stationary flow rate, liquid must be pressurized to a few thousands of 
pounds per square inch. 
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A HIGH PERFORMANCE LIQUID CHROMATOGRAPHY CONSISTS OF THE 
FOLLOWING COMPONENTS 
 Solvent delivery system 
 Pump 
 Solvent degassing system 
 Gradient elution devices 
 Sample introduction system 
 Injectors  
 Detectors 
1.3. METHOD DEVELOPMENT 
INTRODUCTION 
Method development usually requires selecting the method requirements and 
deciding on what type of instrumentation to utilize and why. In the development 
stage decisions regarding choice of column, mobile phase, detectors and method of 
quantitation must be addressed. There are several reasons for developing new 
methods of analyte: 
 There may not be a suitable method for a particular analyte in the specific 
sample matrix. 
 Existing method may be too expensive, time consuming, or energy intensive, 
or they may not be easily automated. 
 Existed method may not provide an adequate sensitivity or analyte selectivity 
in sample of interest. 
 There may be a need for an alternative method to confirm, for legal, or 
scientific reasons, analytical data originally obtained by existing methods. 
 Next, it is necessary to translate the goals of the method into a method 
development design. Goals for a new or a new improved analytical method 
might include the following: 
 Qualitative identification of the specific analyte (x) of interest providing some 
structural information to confirm “general behavior.” (eg. Retention time, color 
change, pH etc) 
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 Quantitative determination at trace levels when necessary that is accurate, 
precise and reproducible in any laboratory setting when performed according 
to established procedures. 
 Decreased cost per analysis by using simple quality assurance and quality 
control procedures. 
 Sample preparations that minimize time, effort, materials and volume of 
sample consumed. 
1.3.1. METHOD DEVELOPMENT IN HPLC INVOLVES THE 
FOLLOWING STEPS: 
Step 1:  Method selection 
The method selection should contain 
 Solubility profile   -   which includes solubility of drug substance in  
    different solvents and at different pH conditions 
 Analytical profile   -   which include analytical profile of the drug  
substance, impurity and degradation products 
 Solubility profile    -   which includes stability profile of the drug  
substance with respect to the storage conditions 
Step 2:  Selection of initial conditions 
This step determines the optimum conditions to adequately retain all analytes i.e., 
ensure no analytes has capacity factor of less than 0.5 (poor retention could result in 
peak overlapping) and no analyte has capacity factor 10-15 (excessive retention 
leads to long analysis time and broad peaks with poor detectability).  
Step 3:  Selectivity optimization 
The aim of this step is to achieve adequate selectivity (peak spacing). The mobile 
phase and stationary phase compositions need to be taken into account. To 
minimize the number of trail chromatograms involved, only the parameters that are 
likely to have a significant effect on selectivity in the optimization must be 
considered. The optimization of mobile phase parameters is always considered first 
as that is much easier and convenient than stationary phase optimization. 
Step 4:  System optimization 
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This is used to find the desired balance between resolution and analysis time after 
satisfactory selectivity has been achieved. The parameters involved include column 
dimensions, column-packing, particle size and flow rate. These parameters may be 
changed without affecting capacity factors or selectivity. 
Step 5:  Method Validation 
Proper validation of analytical methods is important for pharmaceutical analysis 
when ensuring of the continuing efficacy and safety of each batch manufactured 
relies solely in the determination of quality.  Method validation is generally a one-time 
process performed after the method has been developed to demonstrate that the 
method is scientifically sound and that it serves the intended analytical purpose. 
1.3.2. METHOD OPTIMIZATION  
During the optimization stage, the initial sets of conditions that have evolved from the 
first stages of development are improved or maximized in terms of resolution and 
peak shape, plate counts, asymmetry, capacity, elution time, detection limits, limit of 
quantitation and overall ability to quantify the specific analyte of interest. 
Optimization of a method can follow either of two general approaches: 
 Manual 
 Computer driven 
The various parameters that include to be optimized during method development 
 Mode of separation 
 Selection of stationary phase 
 Selection of mobile phase 
 Selection of detector. 
1.3.2.1. Selection of mode of separation 
In reverse phase mode, the mobile phase is comparatively more polar than the 
stationary phase. For the separation of polar or moderately polar compounds, the 
most preferred mode is reverse phase. The nature of the analyte is the primary 
factor in the selection of the mode of separation. A second factor is the nature of the 
matrix. 
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1.3.2.2. Selection of stationary phase/ column 
Selection of the column is the first and the most important step in method 
development because the column is the heart of the separation process. 
 Length and diameter of the column 
 Nature of the packing material 
 Shape of the particles 
 Size of the particles  
 Percentage of Carbon loading 
 Pore volume 
 Surface volume 
 End capping 
1.3.2.3. Selection of separation system/ column 
The column is selected depending on the nature of the solute. Reversed phase 
mode of chromatography facilitates a wide range of columns like dimethyl silane 
(C2), butylsilane (C4), octylsilane (C8), octadecylsilane (C18), base deactivated silane 
(C18) BDS phenyl, cyanopropyl (CN), nitro, amino etc. C18 was chosen for this study 
since it is most retentive one.  
         Peak shape is equally important in method development. Columns that provide 
symmetrical peaks are always preferred. While peaks with poor asymmetry can 
result in: 
 Inaccurate plate number and resolution measurement 
 Imprecise quantitation 
 Degraded and undetected minor bands in the peak tail 
 Poor retention reproducibility 
A column which gives separation of all the impurities and degradants from each 
other and from analyte peak and which is rugged for variation in mobile phase shall 
be selected. 
1.3.2.4. Selection of mobile phase 
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The primary objective in selection and optimization of mobile phase is to achieve 
optimum separation of all the individual impurities and degradants from each other 
and from analyte peak. 
In liquid chromatography, the solute retention is governed by the solute distribution 
factor, which reflects the different interactions of the solute – stationary phase. For a 
given stationary phase, the retention of the given solute depends directly upon the 
mobile phase, the composition of which has to be selected in order to get 
appropriate and required solute retention. The mobile phase has to be adopted in 
terms of elution strength (solute retention) and solvent selectivity (solute separation). 
The following are the parameters, which shall be taken into consideration while 
selecting and optimizing the mobile phase: 
 Buffer 
 pH of the buffer 
 Mobile phase composition 
1.3.2.5. Selection of detector 
The detector was chosen depending upon some characteristics property of the 
analyte like UV absorbance, fluorescence, conductance, oxidation, reduction etc. 
Characteristics that are to be fulfilled by a detector to be used in HPLC determination 
are: 
 High sensitivity 
 Facilitating trace analysis 
 Negligible base line noise 
 To facilitate lower detection 
 Larger linear dynamic range 
 Lower dead volume 
 Non destructive to sample 
 Inexpensive to purchase and operate 
 
1.4 ANALYTICAL PARAMETERS AS PER ICH GUIDELINES 
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The objective of validation of analytical procedure is to demonstrate that it is suitable 
for its intended purpose. 
1.4.1. TYPES OF ANALYTICAL PARAMETERS  
The objective of validation of analytical procedures is directed to the most common 
types of analytical procedures: 
 Identification tests 
 Quantitative tests for impurities content 
 Limit tests for control of impurities 
The objective of the analytical procedure should be clearly understood since this will 
govern the validation characteristics which need to be evaluated. Typical validation 
characteristics which should be considered are listed below: 
 Accuracy 
 Precision 
 Range  
 Specificity 
 Linearity 
 Detection Limit 
 Quantification Limit 
 Ruggedness 
 Robustness 
1.4.1.1.Accuracy 
The closeness of agreement between the value which is accepted either as a 
conventional true value or an accepted reference value and the value found.  
1.4.1.2. Precision: 
The precision of an analytical procedure expresses the closeness of agreement 
between a series of measurements obtained from multiple sampling of the 
homogenous sample under the prescribed conditions. A more comprehensive 
definition proposed by the ICH divides precision into three types. 
 Repeatability 
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 Intermediate Precision 
 Reproducibility 
 
 Repeatability 
Repeatability is the precision of the method under the complete operating conditions 
over a short period of time. One aspect of this is instrumental precision. A second 
aspect is sometimes termed as intra-assay precision and involves multiple 
measurements of the same sample by the same analyte under the same conditions. 
 Intermediate Precision 
Intermediate precision is the agreement of complete measurements when the same 
method is applied many times within the same laboratory. This can include full 
analysis on different days, instruments or analytes, but would involve multiple 
preparations of samples and standards. 
 Reproducibility 
Reproducibility examines the precision between laboratories and is often determined 
in collaborative studies or method transfer experiments. 
Precision often is expressed by the standard deviation or relative standard deviation 
of the dataset. 
1.4.1.3. Range 
The range of a method can be defined as the upper and lower concentration for 
which the analytical method has adequate accuracy, precision and linearity. The 
range of concentration examined will depend on the type of method and its use. 
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1.4.1.4. Specificity 
Specificity is the ability to assess the analyte in the presence of components, which 
may be expected to be present. Assuring specificity is the first step in developing 
and validating a good method. 
1.4.1.5. Linearity 
The linearity of an analytical procedure is its ability to obtain test results, which are 
directly proportional to the concentration of analyte in the sample. Linearity can be 
assessed by performing single measurements at several analyte concentrations. A 
linearity correlation coefficient above 0.999 is acceptable for most methods, 
especially for major components in assay methods. The range of an analytical 
procedure is the interval between the upper and lower concentration of analyte in the 
sample. 
1.4.1.6.Detection Limit: 
The Detection Limit of an individual analyte procedure is the lower amount of analyte 
in a sample which can be detected but not necessarily qualitated as an exact value. 
The detection limit (LOD) may be expressed as:     
                           LOD   =    3.3σ/S        
where ,      σ    =   the standard deviation of the response 
                  S    =    the slope of the calibration curve (of the analyte) 
1.4.1.7. Ruggedness 
Method ruggedness is defined as the reproducibility of results when the method is 
performed under actual use conditions. This includes different analysts, laboratories, 
columns, instruments, sources of reagents, chemicals, solvents and so on. Method 
ruggedness may not be known when a method is first developed, but insight is 
obtained during subsequent use of that method. 
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1.4.1.8. Robustness 
The concept of robustness of an analytical procedure has been defined by the ICH 
as “a measure of its capacity to remain unaffected by small, but deliberate variation 
in method parameters.” The most important aspect of robustness is to develop 
methods that allow for expected variations in the separation parameters. 
1.5 System suitability parameters: 
System suitability of the methods is performed by calculating the chromatographic 
parameters namely column efficiency, resolution, peak asymmetry factor and 
capacity factor on the repetitive injection of standard substances using the following 
formula: 
Retention time (Rt) is the time of elution of peak maximum after injection of sample. 
Resolution (Rs) is the difference between the retention times of two solutes divided 
by their average peak width. The ideal value of (Rs ) is 1.5 
                     Rs = (tR2 ¯ tR1)/(W1+ W2)/2 
Where Rt1 and Rt2 are the retention times of component 1 and 2, 
W1 and W2 are peak widths of components 1 and 2 respectively. 
Column Efficiency (N) or Band broadening of a column is measured by the 
number of theoretical plates per meter. It is a measure of band spreading of a peak. 
Similar the band spread, higher is the number of theoretical plates, indicating good 
column and system performance. Column with N ranging from 5000 to 100000 
plates/ meter are ideal for a good separation. 
         N = 16(t/w) 2    or   
          N = 5.54(t/w1/2)2 
Where, 
 N = width of the peak at its base, obtained by extrapolating the relatively straight 
sides of the peak to the Baseline. 
W1/2 = width of the peak at half height, obtained directly by electronic integrators. 
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Capacity factor (k’) is a measure of how well the sample molecule is retained by a 
column during an isocratic separation. The ideal value of (k’) ranges from 2-10.                             
                                           k’  =  V1−V0/V0 
Where,      V1 is the retention volume at the apex of the peak (solute)        
                  V2 is the void volume of the system. 
Selectivity (∞) is a measure of relative retention of two components in a mixture. 
Selectivity is the ratio of the capacity factors of both peaks, and the ratio of its 
adjusted retention times. In general, if the selectivity of two components is equal to 1, 
then there is no way to separate them by improving the column efficiency. The ideal 
value of ∞ is 2. 
         Selectivity (∞) = V2−V0/V1−V0 =   k’1/k2’ 
Where V0 is the void volume of the column 
V2 and V1 are the retention volumes of the second and first peaks, respectively. 
Peak Asymmetry Factor (As) can be used as a criteria of column performance. For 
a well packed column, an asymmetry factor of 0.9 to 1.1 should be achievable. 
                       As = b/a                      
Where a & b are the distances on either side of the peak midpoint. 
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total column inject cell connect
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2. DRUG PROFILE 
 
2.1 INDAPAMIDE 
DRUG NAME          :    Indapamide 
CHEMICAL STRUCTURE         :   
                               
 
 
 
CHEMICAL FORMULA        :    C16H16ClN3O3S     
MOLECULAR WEIGHT        :    365.8 g/mol 
IUPAC NAME         :   4-chloro-N-[(2RS)-2-methyl-2,3-dihydro-1H- 
      indol-1-yl-3-sulphamoyl benzamide. 
DESCRIPTION         :   White or Almost white powder. 
SOLUBILITY         :   Partially insoluble in water, soluble in  
                                                       ethanol (96 per cent) 
CATEGORY          :   Thiazide like Diuretic. 
MELTING POINT         :   185°C 
DOSAGE AND ADMINISTRATION:   1.25 mg once a day to control high 
                                                             pressure. 
 
MECHANISM OF ACTION:   Indapamide is a new oral antihypertensive 
diuretic and antihypertensive agent. The drug appears to have a unique 
mechanism of action, combining diuretic effects with a direct vascular action, 
presumably secondary to calcium channel blockade.   Accordingly, calcium 
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channel blockers, block influx of extracellular calcium through ion selective 
channels in the membrane both in cardiac and smooth muscle.  
The administration of a fixed combination of perindopril and indapamide to a 
broad range of patients with type 2 diabetes mellitus is associated with 
reduced risks of major vascular events, including death.  
ADVERSE EFFECTS:    
 dry mouth, thirst, nausea, vomiting; 
 feeling weak, drowsy, restless; 
 fast or uneven heartbeat;  
 Muscle pain or weakness. 
BRAND NAME :    
Lozol 
Apo-indapamide 
Natrix 
Natilix 
 OFFICIAL  :      
British pharmacopoeia. 
United State Pharmacopoeia. 
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2.2 PERINDOPRIL ERBUMINE 
 
DRUG NAME   :  Perindopril erbumine 
CHEMICAL STRUCTURE    : 
                        
CHEMICAL FORMULA           :  C19H32N2O5 . C4H11N 
MOLECULAR WEIGHT           :  441.6 g/mol 
IUPAC NAME   : 2-methylpropan-2-amine 
(2S,3aS,7aS)- 
      1-[(2S)-2-[[(1S)-1- (ethoxy carbonyl)  
      butyl] amino]propanoyl]octahydro-
1H-  
Indol-2-carboxylate. 
DESCRIPTION   : White or Almost white, slightly  
hygroscopic, crystalline powder. 
SOLUBILITY              :        Freely soluble in water and in ethanol  
(96 per cent), soluble or sparingly soluble in 
methylene chloride. 
CATEGORY               : Angiotensin converting Enzyme 
Inhibitor 
MELTING POINT              :   537.4°C 
 
DOSAGE AND ADMINISTRATION:  Perindopril is taken in 4 mg or 8 mg 
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MECHANISM OF ACTION       :    Perindopril is the free acid form of 
perindopril erbumine, is a pro-drug and metabolized in vivo by hydrolysis of 
the ester group to form perindoprilat, the biologically active metabolite, inhibits 
ACE in human subjects and animals. The Perindoprilat lowers blood pressure 
by inhibition of ACE activity. ACE is a peptidyl dipeptidase that catalyzes 
conversion of the inactive decapeptide, angiotensin I, to the vasoconstrictor, 
angiotensin II. Angiotensin II is a potent peripheral vasoconstrictor, which 
stimulates aldosterone secretion by the adrenal cortex, and provides negative 
feedback on renin secretion. Inhibition of ACE results in decreased plasma 
angiotensin II, leading to decreased vasoconstriction, increased plasma renin 
activity and decreased aldosterone secretion. The latter results in diuresis and 
natriuresis and may be associated with a small increase of serum potassium. 
ADVERSE EFFECTS:  
 Cough 
 fatigue 
 headache 
 disturbances of mood and/or sleep 
BRAND NAME:   
Aceon 
Apo-perindopril 
Coversyl 
OFFICIAL: 
British Pharmacopoeia. 
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     3. LITERATURE REVIEW 
 
3.1. Jignesh et al.,(2011), performed Absorption factor method for 
perindopril erbumine and amlodipine besylate at wavelength maxima 215 nm 
and 237 nm respectively. Amlodipine besylate was shown linear at 237 nm 
but Amlodipine besylate also showed absorbance at 215nm and given 
interference in determination of Perindopril erbumine. Quantitative estimation 
of Perindopril erbumine was carried out by subtracting interference of 
Amlodipine besylate using experimentally calculated absorption factor.  
3.2. Darshana kartilal modi et al.,(2011), developed simultaneous 
equation method for the measurement of absorbances at two wavelengths 
210.4nm (Ȝmax of perindopril) and 241.2nm (Ȝmax of indapamide) in 
methanol. The linearity was observed in the concentration range of 24 – 56 µg 
mL-1 for perindopril and 7.5 – 17.5 µg mL-1 for indapamide. The method 
showed good reproducibility and recovery with % RSD less than 2.  
3.3. Juddy joseph et al., (2011), proposed the Simultaneous Estimation 
of Perindopril erbumine and Indapamide by RP-HPLC in Pharmaceutical 
Dosage forms. The determination was carried for a runtime of 20min at 40˚C 
on Inertsil ODS-3V column having 250mm x 4.6mm with 5ȝm particle size and 
potassium dihydrogen phosphate buffer adjusted to pH 3.0 using ortho 
phosphoric acid and acetonitrile (60:40 v/v) was used as eluent at a constant 
flow rate of 1.0ml/min with UV detection wavelength of 215nm. The retention 
time of PE and ID was about 11.9 and 4.9min with correlation coefficient of 
0.9992 and 0.9990 respectively. The linearity was established at 8-24ȝg/ml for 
PE and 2.5-7.5ȝg/ml for ID and the mean recovery for both drugs were found 
to be 100.3% at a load volume of 50ȝl. 
 
3.4. A.K. Pathak et al., (2011), developed Chromatographic separation 
on Perindopril  and Indapamide  by using BDS hypersil C18 column 
(25cm×4.6mm, 5 µm ) with a mobile phase comprising of mixture of 
potassium dihydrogen phosphate buffer (pH 2.6) and acetonitrile (65:35) at a 
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flow rate of 1.5 ml/min with detection at 210 nm. Separation was completed in 
less than 15 min.  
 
3.5.Patel Amit R. et al., (2011), performed simultaneous estimation. The 
separation was achieved on Telmisartan and Indapamide by RP-HPLC by 
using an Amazone C18, 5 µm, 150 x 4.6 mm the mobile phase (Buffer: 
acetonitrile: methanol) (45+25+30) Potassium dihydrogen phosphate & 
Triethaylamine pH 3.0 with ortho phosphoric acid buffer flow rate of 1 ml/min 
and UV detection at 285 nm. Comprehensive stress testing of telmisartan and 
indapamide Rt= 4.7 min, 10.7 min was according to the ICH guideline Q1A 
(R2). The linearity of the proposed method was in the range of 6-22.5 
microg/mL (r2 = 0.999) for telmisartan and 11.2-42 µg/ml (r2 = 0.9997) for 
indapamide. 
  
3.6. C.Koza, et al., (2011), has developed HPLC method involved by 
using HiQSil-C-18W ODS, (250 mm × 4.5 mm 5µm),  column and mobile 
phase was ACN: water in proportion of 50:50 v/v, pH adjusted to 3.2 ± 0.1 
with 1 % o-phosphoric acid. The flow rate was 1.0 mLmin-1 and effluent was 
monitored at 210 nm. The retention time of Losartan potassium and 
perindopril erbumine were eluted at 6.7 min and 4.5 min respectively. The 
method was found to be linear in the range of 2-18 g/l for both the drug. The 
coefficient of variance for both the drug was more than 0.999. The mean 
percentage recovery was found to be 98.40 % for Losartan potassium and 
97.50 % for perindopril erbumine. The limits of quantification of Losartan 
potassium and perindopril erbumine were found to be 0.109/gmL-1 and 
0.041/gmL-1.  
 
         3.7. Mohit G Dewani et al., (2011), proposed the simultaneous 
estimation of Indapamide and Perindopril by HPTLC, here the plates precoated with 
silica gel 60 F254 were used. The mobile phase used was Dichloromethane: 
Methanol : Glacial acetic acid in the ratio of 9.5:0.5:0.1 v/v/v. Both the drugs showed 
considerable absorbance at 215 nm. Linearity was obtained in the concentration 
range of 1-5 ȝg/band and 100-500 ng/band for perindopril and indapamide 
respectively.  
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3.8. Jodia et al., (2010), performed the stability indicating assay method 
for simultaneous determination of Perindopril and Indapamide by RP-HPLC 
and the separation was achieved on an XTerra RP18, 5 microm, 150 x 4.6 
mm id column at 55 °C by using the mobile phase sodium dihydrogen 
phosphate  buffer (pH 2.0; 0.005 M) acetonitrile (75 + 25, v/v) at a flow rate of 
1 ml/min and UV detection at 215 nm. Comprehensive stress testing of 
perindopril and indapamide was carried out according to the ICH guideline 
Q1A (R2). The specificity of the method was determined by assessing 
interference from the placebo and by stress testing of the drug (forced 
degradation).The linearity of the proposed method was investigated in the 
range of 24-56 microg/mL (r2 = 0.9993) for perindopril and 7.5-17.5 
µg/m(r2=0.9992) for indapamide. 
  
 
3.9. Abdalla Elshawana et al., (2009), developed the LC method for 
the determination of Perindopril and Indapamide. The drugs were separated 
at room temperature on a 250 mm × 4.6 mm, 5-ȝm particle size, cyanopropyl 
column with 10 mM KH2PO4, pH 6.0-methanol 55:45 (v/v) as mobile phase at 
a flow rate of 1 ml min−1. Detection was at 210 nm.  
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4. AIM AND OBJECTIVE 
 
   4.1. AIM: 
The aim of the work is to develop a precise, accurate, simple and reliable, less time 
consuming validated RP-PLC method for Indapamide and Perindopril erbumine in 
bulk and tablet dosage form. 
   
   4.2. OBJECTIVE: 
 To develop new, simple, sensitive, accurate and economical analytical 
method for the simultaneous estimation of Indapamide and Perindopril 
erbumine. 
 To validate the proposed method in accordance with ICH guidelines for the 
intended analytical application.  
 To apply  the  proposed  method  for  analysis  of  these  drugs  in  their          
combined dosage form. 
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6. EXPERIMENTAL WORK  
6.1. ANALYTICAL METHOD DEVELOPMENT FOR THE ESTIMATION 
OF INDAPAMIDE AND PERINDOPRIL ERBUMINE BY RP-HPLC 
METHOD: 
                                                 Instruments used 
HPLC Instrument Shimadzu LC 10 AT pump 
Spinchrome software 
UV detector SPD 10A 
Injector Rheodyne 
Column YMC column, 150 x 4.6mm, 3µ 
UV Spectrophotometer Thermo electron corporation 
pH meter Adwa-AD 1020 
Electronic Balance AFROSET FX-400 
Ultra sonicator Elma S 300H 
Pipettes, burettes, beakers Borosil 
 
Chemicals and Reagents used 
1. Indapamide 
2. Perindopril erbumine 
3. Water HPLC grade 
4. Acetonitrile HPLC grade 
5. Ammonium dihydrogen phosphate 
6. Ortho phosphoric acid 
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6.1.1. Selection of Mobile Phase: 
Indapamide and Perindopril erbumine are marketed as combined dosage 
formulation. The proposed method for the estimation of Indapamide and 
Perindopril erbumine required adequate resolution of the two drug peaks in 
the chromatogram. Several solvent systems were tried to obtain good 
optimum resolution. 
a) Separation using potassium dihydrogen phosphate : dipotassium 
hydrogen phosphate : acetonitrile (pH 3 using ortho phosphoric acid) 
(40:60v/v)  
In this composition when drug was injected with isocratic programming, it was 
observed that perindopril erbumine  peak was eluted in the void volume 
peaks. 
b) Separation using sodium dihydrogen phosphate : disodium hydrogen 
phosphate : acetonitrile (pH 3 using ortho phosphoric acid) (40:60v/v)  
In this composition when injected, perindopril erbumine was still getting eluted 
in the void volume peak and the resolution between the peaks was too less. 
C) Separation using sodium dihydrogen phosphate : acetonitrile (pH 3 
using ortho phosphoric acid) (40:60v/v)  
In this combination also, perindopril erbumine peak was eluted in the void 
volume peak and the resolution between the peaks was too less. 
D) Separation using Ammonium dihydrogen phosphate : acetonitrile (pH 
2.5 using ortho phosphoric acid) (60:40v/v) 
 By using this combination Indapamide and Perindopril erbumine peaks 
were separated properly with good resolution meeting all the requirements. 
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6.1.2. Selection of wavelength for detection 
Standard stock solution of Indapamide 
Accurately weighed 100mg of Indapamide and transferred into a clean and 
dry 100 ml volumetric flask, dissolved with sufficient volume of diluents. The 
volume made up to 100ml with diluents to obtain the concentration of 
1000µg/ml. 
Working standard solution 
0.1ml of stock solution was further diluted in a 10ml volumetric flask with 
mobile phase to get a concentration of 10µg/ml. 
Standard stock solution of Perindopril erbumine 
Accurately weighed 100mg of Perindopril erbumine and  transferred into a 
clean and dry 100 ml volumetric flask, dissolved with sufficient volume of 
diluents. The volume made up to 100ml with diluents to obtain the 
concentration of 1000µg/ml. 
Working standard solution 
0.1ml of stock solution was further diluted in a 10ml volumetric flask with 
mobile phase to get a concentration of 10µg/ml. 
Preparation of mobile phase 
A mixture of 60 volumes of buffer solution (prepared by dissolving 1.1503gm 
of Ammonium dihydrogen phosphate in 1000 ml of water and adjust the pH to 
2.5 with orthophosphoric acid) and 40 volumes of Acetonitrile. The solution 
was filtered using 0.45 µm membrane filter paper and degassed. 
Procedure 
Indapamide 10µg/ml solution and Perindopril erbumine 10µg/ml solution were 
scanned individually on a UV-visible spectrophotometer in the wavelength 
range of 200 to 400 nm. 
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       The sensitivity of method that uses UV detector depends upon the proper 
selection of wavelength. An ideal wavelength is that gives maximum 
absorbance and good response for both drugs to be detected. 
        Hence a common maximum of 230 nm at which the mixture of drugs 
showing maximum intensity was selected. 
6.1.3. Optimization of column 
The method was performed with various columns like C18 column, hypersil 
column, lichrosorb and inertsil ODS column. YMC (150 x 4.6mm, 3µ) was 
found to be very ideal as it gave a good peak shape and resolution. 
6.1.4. Effect of column temperature 
To improve the peak resolution different temperature conditions were tried 
i.e.,  30,35 & 400c. The best resolution was found at column temperature 400c. 
so, the optimum temperature was kept constant at 40 ºC i.e., ambient 
temperature. 
6.1.5. Optimized Chromatographic conditions 
Instrument                      : HPLC Shimadzu Separation Module LC-20AT  
                                           Prominence liquid chromatograph                                                
Mobile Phase          : Ammonium dihydrogen phosphate : Acetonitrile  
Mobile Phase Ratio        : 60 : 40 v/v 
Diluents           : Mobile phase 
Column           : YMC Column (150 x 4.6mm, 3µ particle size) 
Detector           : 230 nm 
Flow rate           : 1 ml/min 
Runtime           : 10 min 
Injection volume             : 20 µl 
Column oven                   : 40oc 
Temperature 
Inference:  
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By following the above conditions, both the peaks were eluting with 
required resolution and baseline with good signal to noise ratio. All the peaks 
are well distributed throughout the run time. Blank interference and peak 
asymmetry were minimized. 
6.1.6. Determination of Retention time 
Standard stock solution of Indapamide 
Accurately weighed 100mg of Indapamide and transferred into a clean and 
dry 100 ml volumetric flask, dissolved with sufficient volume of diluents. The 
volume made up to 100ml with diluents to obtain the concentration of 
1000µg/ml. 
Working standard solution 
10 ml of stock solution was further diluted in a 50 ml volumetric flask with 
mobile phase to get a concentration of 200µg/ml. 
Standard stock solution of Perindopril erbumine 
Accurately weighed 100mg of Perindopril erbumine and transferred into a 
clean and dry 100 ml volumetric flask, dissolved with sufficient volume of 
diluents. The volume made up to 100ml with diluents to obtain the 
concentration of 1000µg/ml. 
Working standard solution 
10 ml of stock solution was further diluted in a 50 ml volumetric flask with 
mobile phase to get a concentration of 200µg/ml. 
Preparation of mobile phase 
A mixture of 60 volumes of buffer solution (prepared by dissolving 1.1503gm 
of Ammonium dihydrogen phosphate in 1000 ml of water and adjusted the pH 
to 2.5 with ortho phosphoric acid) and 40 volumes of Acetonitrile. Filter the 
solution with 0.45 µm filter paper and degassed. 
 
Procedure 
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20µl of each of these working standard solutions of Indapamide and 
Perindopril erbumine were injected separately with flow rate of 1 ml/min. Peak 
area and retention time in chromatogram was observed, recorded in figure1. 
 
6.2. VALIDATION OF DEVELOPED HPLC METHOD FOR 
ESTIMATION OF INDAPAMIDE AND PERINDOPRIL ERBUMINE 
A HPLC method had been developed for the simultaneous estimation of 
Indapamide and Perindopril erbumine using YMC column (150 x 4.6mm, 
3µm), mobile phase Acetonitrile : Buffer (40 : 60 v/v), pH of buffer adjusted to 
2.5 with ortho phosphoric acid, detection wavelength at 230 nm at flow rate 1 
ml/min, at retention time 4.32 for indapamide and 2.31 for perindopril 
erbumine. 
6.2.1. System suitability 
These tests were based on the concept that the equipment, electronics, 
analytical operations and samples to be analysed which constitutes an 
integral system that can be evaluated as such. This test ensures that the 
analytical system was working properly and can give accurate and precise 
results. 
Preparation of Standard Stock Solution: 
             Accurately weighed and transferred 100mg of Indapamide and 50mg 
Perindopril erbumine working standard and transferred into a 100ml clean dry 
volumetric flask containing mobile phase. The solution was sonicated for 
about 10mins and then made up to volume with mobile phase. 
Preparation of working standard solution 
100 ml of standard stock solution was taken in a 50 ml volumetric flask and 
the volume was made up to 50 ml with mobile phase, to get a concentration of 
200µg/ml. 
 
Procedure 
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Standard solution preparation was injected into chromatographic system and 
chromatograms were recorded (figure 2) and tabulated (table 1) 
Acceptance criteria 
1. Tailing factor should be Not More Than 2.0. 
2. Theoretical plates should be Not Less Than 2000. 
 
6.2.2. Linearity: 
The linearity of the analytical method constitutes its ability to elicit test results 
which are directly proportional to the concentration of the analyte in the 
sample. 
Preparation of Standard Stock Solution: 
             Accurately weighed and transferred 100mg of Indapamide and 50mg 
Perindopril erbumine working standard and transferred into a 100ml clean dry 
volumetric flask containing mobile phase. The solution was sonicated for 
about 10mins and then made up to volume with mobile phase. 
Preparation of Level – I (20mcg solution of Indapamide and Perindopril 
erbumine):  
0.2ml of stock solution was taken in 10ml of volumetric flask, which was 
diluted up to the mark with mobile phase.  
Preparation of Level – II (40mcg solution of Indapamide and Perindopril 
erbumine): 
0.4ml of stock solution was taken in 10ml of volumetric flask, which was 
diluted up to the mark with mobile phase.  
Preparation of Level – III (60mcg solution of Indapamide and Perindopril 
erbumine):  
0.6ml of stock solution was taken in 10ml of volumetric flask, which was 
diluted up to the mark with mobile phase. 
Preparation of Level – IV (80mcg solution of Indapamide and Perindopril 
erbumine): 
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0.8ml of stock solution was taken in 10ml of volumetric flask, which was 
diluted up to the mark with mobile phase. 
Preparation of Level – V (100mcg solution of Indapamide and Perindopril 
erbumine) 
1.0ml of stock solution was taken in 10ml of volumetric flask, which was 
diluted up to the mark with mobile phase. 
Preparation of Level – VI (120mcg solution of Indapamide and 
Perindopril erbumine)  
1.2ml of stock solution was taken in 10ml of volumetric flask, which was 
diluted up to the mark with mobile phase. 
Procedure:  
Solution of different concentrations (level I - VI) were injected into the 
chromatographic system and measured the peak area. Chromatogram for 
Linearity of Indapamide and Perindopril erbumine  from Level I ― VI are given 
in Figure 5, 6, 7, 8, 9, 10 and Chromatogram Linearity report was given  
(figure11).  
A calibration curves were plotted for linearity having concentration against 
peak area and calculated the correlation coefficient (figure 3, 4). 
The results were tabulated (table 2, 3, 4) 
 
 
6.2.3. Assay: 
A solution of 20µl standard, sample separately were injected into the 
chromatographic system and the peak areas of the Indapamide and 
Perindopril erbumine were measured and the percentage assay was 
calculated by using the formulae. Chromatograms were recorded (figure 34, 
35) and tabulated (table 13, 14), measured the peak responses.  
                                              At        Ws      DT        P        Avg. Wt 
  Assay percentage  =         ------- x ------ x ------ x ------ x ---------------- x 100 
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                                      As         Ds       Wt      100    Label Claim 
 Where:  
                            At         =   average area counts of sample preparation. 
                            As        =   average area counts of standard preparation. 
                            W         =    Weight of working standard taken in mg. 
                            P         =    Percentage purity of working standard 
                            LC       =    Label claim  
                            DT        =    Dilution factor of test sample.  
 
6.2.4. Accuracy: 
The accuracy of an analytical method is the closeness of test results obtained 
by that method to the true value. Accuracy may often expressed as percent 
recovery by the assay of known added amounts of analyte. 
Preparation of Standard stock solution:  
Accurately weighed 100mg of Indapamide and 50mg Perindopril erbumine 
working standard was transferred into a 100ml clean dry volumetric flask 
containing mobile phase. The solution was sonicated for about 10mins and 
then made upto volume with mobile phase. 
Procedure: 
The standard solutions of concentrations 8.55µg/ml, 10.45µg/ml, 12.35µg/ml of 
Indapamide and 22.5µg/ml, 27.5µg/ml, 32.5µg/ml of Perindopril erbumine were 
injected into chromatographic system. Calculated the amount found and 
amount added for Indapamide and Perindopril erbumine and also calculated 
the individual recovery and mean recovery values. The Chromatograms were 
recorded (figure 12, 13, 14, 15). The results were tabulated (table 5, 6) 
 
6.2.5. System Precision:  
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The system precision was checked by using standard chemical substance to 
ensure that the analytical system was working properly. The retention time 
and area of six determinations was measured and percentage Relative 
Standard deviation was calculated. 
Preparation of Standard stock solution: 
             Accurately weighed 100mg of Indapamide and 50mg perindopril 
erbumine working standard transferred into a 100ml clean dry volumetric flask 
containing mobile phase. The solution was sonicated for about 10mins and 
then made up to volume with mobile phase. 
Procedure: 
The standard solution was injected for five times and measured the area for all 
five injections in HPLC. The percentage Relative Standard  Deviation for the area 
of five injections was found to be within the specified limits. The Chromatograms 
were recorded (figure 16, 17, 18, 19, 20) and the results were tabulated (table 
7, 8) 
 
Standard Deviation    
    S.D (σ)  =  1
)xx( 2i


n
 
              Where, x=Sample, 
     xi = Mean value of samples.  
     n=number of samples.  
 
              Coefficient of variance / Relative standard deviation 
C.V =         Standard Deviation  
                 Mean  
Acceptance Criteria: 
X
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The % RSD for the retention time of five standard injections results should be 
NMT1%. 
The % RSD for the area of five standard injections results should be NMT2%. 
 
6.2.6. Method precision (Repeatability) 
Method precision indicates whether a method is giving consistent results for a 
single batch, usually applied to standardization of methodology. 
Preparation of Standard stock solution: 
             Accurately weighed 100mg of Indapamide and 50mg perindopril 
erbumine working standard transferred into a 100ml clean dry volumetric flask 
containing mobile phase. The solution was sonicated for about 10mins and 
then made upto volume with mobile phase. 
 
Procedure: 
The standard solution was injected for five times and chromatograms were 
recorded in HPLC. The percentage Relative Standard Deviation was calculated 
for concentration of drug in triplicates. The results obtained were reported 
(figure21, 22, 23, 24, 25) and tabulated (table 9, 10) 
Acceptance Criteria 
The % RSD value for assay should be NMT 2% 
 
 6.2.7. Robustness 
The Robustness of an analytical method is a measure of its capacity to 
remain unaffected by small but deliberate variations in method parameters 
and provides an indication of its reliability during normal usage. 
             The robustness of the proposed method was determined by analysis 
of aliquotes from homogenous lots by differing physical parameters like 
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volume of injection, wavelength which may differ but the responses were still 
within the limits of the assay. 
(a) Effect of variation of Flow rate: 
  A study was conducted to determine the effect of variation in flow rate by 
injecting 0.9and 1.1ml/min. Standard solution was prepared and injected into 
the HPLC system. The retention time values were measured.  
(b) Effect of variation of wavelength: 
          A study was conducted to determine the effect of variation in wavelength.         
Standard solution was prepared and injected into the HPLC system at 218nm    
and 224nm. The effect of variation in wavelength was evaluated. 
The results were tabulated (table 11) and recoded (figure 26, 27, 28, 29) 
 
Acceptance criteria: 
1. Tailing factor should be NMT 2.0 for variation in flow rate. 
2. The %RSD should be NMT 2.0 for variation in flow rate.  
    3. Tailing factor should be NMT2.0 for variation in wavelength. 
    4. The %RSD should be NMT2.0 for variation in wavelength.                  
    
 6.2.8. Ruggedness: 
Ruggedness is the degree of reproducibility of the results obtained under a 
variety of conditions. It was checked that the results were reproducible under 
differences in conditions, analysts and instruments. Hence the proposed 
method was found to be rugged. The Chromatograms were recorded (figure 
30, 31).The results were tabulated (table 12). 
Preparation of Stock Solution:                                                                 
    
             Accurately weighed 100mg of Indapamide and 50mg Perindopril 
erbumine working standard transferred into a 100ml clean dry volumetric flask 
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containing mobile phase. The solution was sonicated for about 10mins and 
then made up to volume with mobile phase. 
            From the above solution 1.0ml was taken and made up to 10ml using 
mobile phase (100mcg). 
Procedure: 
The standard solution (100mcg) was injected for by different analysts and the 
area for injections in HPLC was measured. The percentage Relative Standard 
Deviation for the area of replicate injections was found to be within the specified 
limits. 
 
 
6.2.9. Specificity 
Specificity is the ability to access unequivocally that the analyte in the 
presence of components which may be expected to be present. Typically 
these might include impurities, degradation products and matrix components. 
Preparation of standard stock solution  
Accurately weighed standard drugs Indapamide and Perindopril erbumine 100 
mg each was transferred in clean, dry 100 ml volumetric flask and dissolved in 
few ml of diluents. The volume made up to 100 ml with diluents to obtain the 
concentration of 1000µg/ml. 
Preparation of working standard solution 
10 ml of standard stock solution of Indapamide and Perindopril erbumine were 
taken separately into 50 ml volumetric flask and the volume was made up to 
50 ml using mobile phase to get the concentration of 200µg/ml. 
Procedure 
20µl of each solution of mobile phase, Indapamide and Perindopril erbumine 
working standard solutions were injected into the chromatographic system 
and chromatograms obtained are recorded (figure 32, 33) 
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7.RESULTS AND DISCUSSIONS 
7.1.ANALYTICAL METHOD DEVELOPMENT FOR THE ESTIMATION OF 
INDAPAMIDE AND PERINDOPRIL ERBUMINE BY RP-HPLC METHOD 
Selection of mobile phase 
Several solvent systems were tried to get good optimum resolutions of Indapamide 
and Perindopril erbumine in the chromatogram. The chromatogram is presented 
below. 
Figure 1. Chromatogram showing peak separation with Buffer (Ammonium 
dihydrogen phosphate) pH 2.5 with ortho phosphoric acid : Acetonitrile (60:40), as 
mobile phase 
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Report 
It was found that peaks of Indapamide and Perindopril erbumine were well resolved 
with the solvent system of Acetonitrile and Buffer (pH 2.5) in the ratio 40:60 with 
ortho phosphoric acid. 
 
 
 
7.2. METHOD VALIDATION PARAMETERS 
7.2.1. SYSTEM SUITABILITY 
This parameter ensures that the analytical system is working properly and can give 
accurate and precise results. A 20µl solution of Indapamide and Perindopril 
erbumine solution was injected and the parameters like theoretical plates per 
column and tailing factor were calculated. 
Figure 2. System suitability chromatogram for Indapamide and Perindopril 
erbumine 
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Table 1.System suitability parameter for Indapamide and Perindopril erbumine 
Parameters Indapamide Perindopril 
erbumine 
Acceptance 
criteria 
Theoretical plates 6004 2831 NLT 2000 
Tailing factor 1.3887 1.750 NMT 2.0 
Height 25.88 138.81 - 
Resolution                           11.020 
 
Report 
The system suitability parameters were developed for both Indapamide and 
Perindopril erbumine were found to be within acceptance criteria. 
7.2.2.LINEARITY 
The linearity parameter was performed to ensure that the test results are directly 
proportional to the concentration of analyte sample. For the linearity 20µl of each of 
working standard solution of Indapamide and Perindopril erbumine were injected 
into HPLC system. The peak area and concentration were plotted to get a standard 
calibration curve. The correlation coefficient was calculated. The results obtained 
were tabulated below. 
Table 2. Linearity of Indapamide and Perindopril erbumine 
S Indapamide Perindopril erbumine  
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Table 3. Linearity Report of Indapamide and Perindopril erbumine 
       Parameter Acceptance criteria Result observed 
Indapamide Perindopril 
erbumine 
Correlation  
co-efficient 
NLT 0.996 0.999 0.999 
 
Figure 3. Standard calibration curve for Indapamide 
I
.
N
o 
Concent
ration 
(mcg/ml
) 
Peak area Concent
ration 
(mcg/ml
)  
Peak area 
1 2 41.899 10 184.717 
2 4 81.739 20 334.557 
3 6 121.039 30 502.17 
4 8 162.628 40 670.6 
5 10 204.908 50 836.134 
6 12 239.872 60 972.623 
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Figure 4. Standard calibration curve of Perindopril erbumine 
 
 
Table 4. Linearity of Indapamide and Perindopril erbumine 
Parameter Results 
Indapamide Perindopril 
erbumine 
Slope 20.01 32.07 
Intercept +1.915 +22.19 
Correlation co-efficient 0.999 0.999 
Percentage curve fitting 99.9% 99.9% 
 
Figure 5. Chromatogram for Linearity of Indapamide and Perindopril erbumine 
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Figure 6. Chromatogram for Linearity of Indapamide and Perindopril erbumine 
level 2 
Figure 7. Chromatogram for Linearity of Indapamide and Perindopril erbumine 
level 3 
Figure 8. Chromatogram for Linearity of Indapamide and Perindopril erbumine 
level 4 
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Figure 9. Chromatogram for Linearity of Indapamide and Perindopril erbumine 
level 5 
 
Figure 10. Chromatogram for Linearity of Indapamide and Perindopril erbumine 
level 6 
Figure 11. Linearity Report for Indapamide and Perindopril erbumine 
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Report 
      The proposed method is found to be linear at concentration of 2-12µg/ml for 
Indapamide and 5-30 µg/ml for Perindopril erbumine. The correlation coefficient and 
percentage curve fitting for Indapamide and Perindopril erbumine was found to be 
0.999, 0.999 and 99.9%, 99.9% respectively which are well in the acceptance criteria 
limits. 
 
7.2.3. Accuracy 
This parameter is performed to determine the closeness of test results with that of 
true values which is expressed as % recovery. 
 
Table 5. Accuracy of Indapamide 
S
.
N
o
Concen
tration 
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Recovery (µg) % 
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2
1
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764 
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Table 6. Accuracy of Perindopril erbumine 
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Figure 12. Accuracy of standard preparation of Indapamide and Perindopril 
erbumine 
 
Figure 13. Accuracy of sample preparation of Indapamide and Perindopril 
erbumine 
 
Figure 14. Accuracy of sample preparation of Indapamide and Perindopril 
erbumine 
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Figure 15. Accuracy of sample preparation of Indapamide and Perindopril 
erbumine 
 
Report 
The mean percentage recovery for Indapamide and Perindopril erbumine was found 
to be between 98.48- 99.90 and 99.89-99.96 respectively, which are well within the 
acceptance criteria and hence the method was found to be accurate. 
 
7. 2.4. System Precision 
This method validation parameter was performed to ensure the closeness of results 
between true value and experimental value. Five injections of 20µl volume 
Indapamide and Perindopril erbumine respectively were injected into the system. 
The retention time and peak area were recorded and are presented below. 
 
Table 7. Precision of Indapamide and Perindopril erbumine 
SI.
N
o 
Inject
ion 
numb
er 
Indapamide Perindopril erbumine 
Reten
tion 
Area(
mVs) 
Reten
tion 
Area(
mVs) 
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Figure 16. Precision of Indapamide and Perindopril erbumine (injection 1) 
(100 
µg/ml
) 
time(
min) 
time(
min) 
1 
Injecti
on-1 
4.170 211.42
7 
2.110 838.37 
2 
Injecti
on-2 
4.173 210.66
2 
2.113 837.52
4 
3 
Injecti
on-3 
4.173 209.67
7 
2.117 837.31
4 
4 
Injecti
on-4 
4.173 208.99
2 
2.117 837.41
0 
5 
Injecti
on-5 
4.18 211.08
9 
2.117 837.82
3 
 AVRG 
4.173
8 
210.36
94 
2.114
8 
837.68
82 
 
STDE
V 
0.003
701 
1.0122
51 
0.003
194 
0.4264
4 
 %RSD 0.09 0.48 0 0.05 
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Figure 17. Precision of Indapamide and Perindopril erbumine (injection 2) 
 
Figure 18. Precision of Indapamide and Perindopril erbumine (injection 3) 
 
Figure 19. Precision of Indapamide and Perindopril erbumine (injection 4) 
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Figure 20. Precision of Indapamide and Perindopril erbumine (injection 5) 
 
Table 8. Precision of Indapamide and Perindopril erbumine 
Drug %RSD for RT %RSD for Peak area Accepatance criteria 
Indapamide 0.09 0 NMT 2% 
Perindopril 
erbumine 
0.48 0.05 NMT 2% 
 
Report 
       The %RSD values of retention time and Peak area for five injections of 
Indapamide and Perindopril erbumine were found to be 0.09, 0.48 and 0.0, 0.05 
respectively which are well within acceptance criteria limit. 
7.2.5. Method Precision 
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The method precision was performed to standardize methodology i.e., to check 
whether the developed method is precise. Six injections of 20µl working standard 
solutios of concentration (200:200)µg/ml of Indapamide and Perindopril erbumine 
were injected. Chromatograms were recorded and presented below. The %RSD for 
peak area was calculated. 
Table 9. Method Precision of Indapamide and Perindopril 
 
SI.N
o 
Injection 
number (100 
mcg/ml) 
Indapamide Perindopril erbumine 
Retenti
on time 
Peak 
Area 
Retenti
on time 
Peak 
Area 
1 
Injectio
n-1 
4.190 209.91
6 
2.123 835.04
7 
2 
Injectio
n-2 
4.187 210.93
8 
2.123 835.95
6 
3 
Injectio
n-3 
4.180 210.84
5 
2.120 837.98
7 
4 
Injectio
n-4 
4.187 207.86
2 
2.123 834.22
5 
5 
Injectio
n-5 
4.190 210.26
0 
2.123 839.13
1 
AVRG 4.1868 
209.96
42 2.1224 
836.46
92 
STDEV 
0.00408
7 
1.2483
15 
0.00134
2 
2.0439
76 
%RSD 0.10 0.59 0.06 0.24 
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Figure 21. Method Precision of Indapamide and Perindopril erbumine(injection 1) 
 
Figure 22. Method Precision of Indapamide and Perindopril erbumine (injection 2) 
 
 
Figure 23. Method Precision of Indapamide and Perindopril erbumine (injection 3) 
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Figure 24. Method Precision of Indapamide and Perindopril erbumine (injection 4) 
 
Figure 25. Method Precision of Indapamide and Perindopril erbumine (injection 5) 
 
Table 10. Method precision of Indapamide and Perindopril erbumine 
Drug %RSD of Peak Area Acceptance criteria 
Indapamide 0.59 NMT 2% 
Perindopril erbumine 0.24 NMT 2% 
 
Report 
The %RSD values for Retention time and Peak area for five injections of Indapamide 
and Perindopril erbumine were found to be 0.10, 0.06 and 0.59, 0.24 respectively, 
which are well within acceptance criteria. 
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7.2.6.Robustness 
         This parameter was carried out to check the ability of the system to give 
unaffected results for small deliberate changes in system parameters and 
method parameters. 
Table 11. Robustness of Indapamide and Perindopril erbumine 
 
 
 
Figure 26. Robustness of Indapamide and Perindopril erbumine (0.9ml) 
 
 
 
 
 
Proposed variation Indapamide Perindopril 
erbumine 
Acceptance 
criteria 
Asymmetry factor 
Variation in flow rate 0.9ml 0.137 0.100  
In between 
0.5 and 2.0 
1.1ml 1.345 1.833 
Variation in wavelength 218nm 1.367 1.750 
224nm 1.387 1.750 
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Figure 27.Robustness of Indapamide and Perindopril erbumine (1.1ml) 
 
Figure 28. Robustness of Indapamide and Perindopril erbumine (218 nm) 
 
 
Figure 29. Robustness of Indapamide and Perindopril erbumine (224 nm) 
 
Report 
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 From the above observations it can be concluded that, the method is robust with 
respect to change in flow rate and wavelength. 
 
7.2.7. Ruggedness (Reproducibility) 
Ruggedness is the degree of reproducibility of the results obtained under a variety of 
conditions. It is checked that the results are reproducible under differences in 
conditions, analysts and instruments.  
Table 12. Ruggedness of Indapamide and Perindopril erbumine 
Figure 30.Ruggedness of Indapamide and Perindopril erbumine (Analyst 1) 
 
 
 
 Indapamide Perindopril erbumine 
Retentio
n time 
Peak 
Area 
Retentio
n time 
Peak 
Area 
Analyst(1)(100mc
g) 
4.180 211.08
9 
2.117 837.82
3 
Analyst(2)(100mc
g) 
4.180 211.08
9 
2.117 837.82
3 
AVRG 
4.810 211.08
9 
2.117 837.82
3 
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Figure 31. Ruggedness of Indapamide and Perindopril erbumine (Analyst 2) 
 
Report 
The results are within the acceptance limit, the proposed method is found to be 
rugged. 
 
7.2.8.Specificity 
This parameter was performed to assess and ensure that the impurities, degraded 
products and diluents do not affect the samples analyzed. 20µl of diluents, 
Indapamide, Perindopril erbumine were injected into the system and 
chromatograms recorded and presented below. 
Figure 32. Specificity of Indapamide and Perindopril erbumine in 0.1 M HCl 
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Figure 33. Specificity if Indapamide and Perindopril erbumine in 0.1N NaOH 
 
Report  
The chromatogram of Indapamide and Perindopril erbumine were analyzed and 
there is no interference from diluents, excipients and impurities with peaks of 
Indapamide and Perindopril erbumine. 
 
 
 
7.2.9.ASSAY 
The developed and valideated HPLC method was used to determine Indapamide and 
Perindopril erbumine in combined dosage form (tablets). 
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Formulation used    : Tablet 
Brand Name              : Periguard-G 
Company Name        : Primal Health care Ltd., Mankind pharma 
Procedure                   : 20µl of the sample solutions were injected into HPLC system 
and the 
                                        results obtained are presented below. 
 
 
Table 13. Assay of Indapamide and Perindopril erbumine by RP-HPLC 
 
 
S.no Parameter Indapamide Perindopril 
erbumine 
01 Spl. Area 312.0265              
870.8355 
02 Std.Area 322.4047 929.659 
03 Std. Wt 5.1mg 13.4mg 
04 Spl.Wt 1010.6mg 1010.6mg 
05 LC 0.625mg 1.569mg 
06 Avg.Wt 126.3mg 126.3mg 
07 Std.Purity 99.84% 99.84% 
08 Assay %  99.17078 99.82123 
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Table 14. Assay of Indapamide and Perindopril erbumine by RP-HPLC 
 
 
Figure 34. Chromatogram for assay of Indapamide and Perindopril erbumine 
 Indapamide Perindopril erbumin
Standard 
Rt 
Sample 
Rt 
Standard 
area 
Sample 
area 
Standard 
Rt 
Sample 
Rt 
Stan
area
2.1271 2.197 222.595 315.616 4.190 4.143 865.0
2.1271 2.184 225.793 312.437 4.193 4.157 868.8
N 2.1271 2.1905 224.194 314.0265 4.1915 4.150 866.9
EV 0 0.009192 2.261327 2.247892 0.002121 0.002828 2.692
0.0 0.42 1.01 0.72 0.05 0.07 0.31
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Figure 35. Chromatogram for assay of Indapamide and Perindopril erbumine 
 
Report 
The percentage purity of Indapamide and Perindopril erbumine in Periguard-G 
tablets was found to be in the range. 
 
 
 
 
8. SUMMARY  
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8.1. Table for Validation parameters of RP-HPLC 
     
 
 
 
SN
o 
 
Paramete
rs 
 
Limit 
Proposed HPLC method 
Indapami
de 
Perindopril 
erbumine 
1. Wave 
length 
(nm) 
- 240 nm 210 nm 
2. Linearity - 2-12µg/ml 5-30 µg/ml 
3. Regression 
equation 
- y=20.01x+
1.915 
Y=32.07x+22.
19 
4. 
 
Correlation 
coefficient 
NLT 
0.996 
0.999 0.999 
5. Slope - 20.01 32.07 
6. Intercept - +1.915 +22.19 
7. System 
Precision 
RSD 
NMT 
2% 
0.48 0.05 
8. Method 
Precision 
RSD 
NMT 
2% 
0.59 0.24 
9. % 
Recovery 
98-
102% 
99.54 99.76 
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System suitability parameters were determined. The number of theoretical 
plates per column for Indapamide and Perindopril erbumine was found to be 
6004 and 2831 respectively. The symmetry factor or tailing factor was found 
to be 1.3887 and 1.750 for Indapamide and Perindopril erbumine. The 
resolution of the method was calculated and was found to be 11.020. 
Specificity of the method was determined. The chromatogram of Indapamide 
and Perindopril erbumine were analyzed and there is no interference from 
diluents, excipients and impurities with peaks of Indapamide and Perindopril 
erbumine. 
Linearity  of the drugs response was found to be in the concentration range 
of 2-12µg/ml for Indapamide and 5-30 µg/ml for Perindopril erbumine. The 
correlation coefficient and percentage curve fitting for Indapamide and 
Perindopril erbumine was found to be 0.999, 0.999 and 99.9%, 99.9% 
respectively which are well in the acceptance criteria limits. 
Precision of the system and method was determined. The %RSD values of 
retention time and Peak area for five injections of Indapamide and Perindopril 
erbumine were found to be 0.09, 0.48 and 0.0, 0.05 respectively which were 
well within acceptance criteria limit for system precision. The %RSD values 
for Retention time and Peak area for five injections of Indapamide and 
Perindopril erbumine were found to be 0.10, 0.06 and 0.59, 0.24 respectively, 
which were well within acceptance criteria for method precision. Hence the 
proposed method was found to provide high degree of precision and 
reproducibility. 
Accuracy was determined through recovery studies of Indapamide and 
Perindopril erbumine. The mean percentage recovery for Indapamide and 
Perindopril erbumine was found to be between 98.48- 99.90 and 99.89-99.96 
respectively, which were well within the acceptance criteria and hence the 
method was found to be accurate, indicating no interference of the drugs with 
each other or with the excipients present in the formulation. 
Robustness of the method was determined by changing the flow rate of 
mobile phase slightly in RP-HPLC method. The %RSD of peak area, tailing 
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factor and Theoretical plates were found to be well within the acceptance 
criteria. 
Ruggedness or degree of reproducibility of the results obtained under a 
variety of conditions. It is checked that the results are reproducible under 
differences in analysts. The results are within the acceptance limit, the 
proposed method is found to be rugged. 
Percentage purity of Indapamide and Perindopril erbumine in combination 
was determined and percentage purity was found to be in the 99.17078 and 
99.82123 for Indaapmide and Perindopril erbumine. 
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9.Conclusion 
 
A RP-HPLC method was developed and validated successfully for the 
estimation of Indapamide and Perindopril erbumine in bulk and tablet dosage 
formulation. The methods were found to be accurate, precise, linear, specific 
and reproducible for the simultaneous determination of Indapamide and 
Perindopril erbumine in bulk and tablet dosage form (tablets). 
            Hence these methods can be used for simultaneous estimation of 
Indapamide and Perindopril erbumine in routine table. 
 
Future scope 
         This study can be extended by studying the degradation kinetics of 
Indapamide and Perindopril erbumine determination by second order 
derivative and simultaneous UV method, HPTLC method and also its 
estimation in plasma and biological fluids. 
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